Abstract
), the top 10 36 cancer-associated CpGs included a site near RPTOR that is involved in the 37 mTOR pathway, and the candidate tumor suppressor genes REC8, KCNQ1, and 38 ZSWIM5. However, only the CpG in RPTOR (cg08129331) was replicated in an 39 independent data set. Analysis of within-individual change from baseline to Year 40 6 found significant correlations between the rates of change in methylation in 41 abnormal epigenomic changes within tumor cells would hold the most impact, 81 there is developing evidence that methylation changes relevant to cancer 82 progression can be detected in circulating blood. For example, global changes in 83 repetitive elements as well as targeted CpG methylation found in DNA from blood 84 cells have been reported for multiple cancer types [11] [12] [13] [14] [15] . This suggests the 85 possibility of a pan-cancer biomarker panel detectable in blood that could 86 precede the clinical detection and diagnosis of cancer [16] . 87
Few longitudinal studies have investigated the time-dependent dynamics in DNA 88 methylation as a potentially important indicator of tumorigenesis [14, 15] . The 89 present study examines the longitudinal restructuring of the methylome over five 90 years and evaluates whether change in CpG methylation is a biomarker of 91 cancer in older adults. Our approach involves dimension reduction techniques 92 and evaluates leukocyte proportions and differential methylation at the level of 93 individual CpGs. Overall, our study defined global and targeted changes in the 94 blood methylome that were correlated to cellular composition, aging, and cancer 95 in the Health ABC cohort. 96 (Additional file 1: Figures S1B, S1C). Since the two samples were assayed on 148 different Sentrix arrays, the outlier status is unlikely to be the result of technical 149 artifact, but rather, flags Per13 as a biological outlier (excluded from downstream 150 analyses). As an additional error checking step to confirm if samples from the 151 same participants paired appropriately with self, we repeated the unsupervised 152 cluster analysis using only 52,033 probes that were filtered out from the main set 153 of probes due to overlap with common single nucleotide polymorphism (SNP) Year from baseline when second DNA sample was collected; two participants had no follow-up
159
DNA and one participant had no baseline (visit year 1) DNA due to low DNA quality/quantity. 
Estimating cellular composition 166
Cellular heterogeneity has a strong influence on DNA methylation, and methods 167 have already been developed to estimate cellular composition of whole blood 168 from genome-wide DNA methylation data [21] [22] [23] . We used the 169 "estimateCellCounts" function in minfi, which implements a modified version of 170 the algorithm by Houseman et al. [23] and relies on a panel of cell-type specific 171
CpGs to serve as proxies for different types of white blood cells. 172
Analyses of DNA methylation data 173
Considering the small sample size of the genome-wide data, we first started with 174 a dimension reduction approach and applied PCA to capture the major sources 175 of global variance in the methylome. The top 5 principal components (PCs) were 176 then related to baseline variables using chi-squared tests for categorical 177 variables (sex and race), and analysis of variance for continuous variables (BMI 178 and age). We also examined the time-dependent change in the PCs with visit 179 year as the predictor variable. Correlations between leukocyte types and the PCs 180
were examined using bivariate analysis. We considered adjudicated cancer 181 diagnosis as the main outcome variable and examined whether methylome-182 based variables differed between those who developed cancer and those who 183 remained cancer-free. 184
Our primary analysis was to evaluate differential methylation at the CpG-level. As 185 in Roos et al. [16] , we first fitted a linear regression model on each probe for the 186 first 5 PCs (β-value ~ PC1 + PC2 + PC3 + PC4 + PC5) to adjust for the effects of 187 confounding variables such as cellular heterogeneity and additional unknown 188 sources of variance. Year 6 (deltaβ = Year 6 -baseline), which was then correlated to time-to-197 diagnosis (i.e., years from baseline to when participant received diagnosis). 198
Data availability 199
The deidentified raw data set with normalized β -values and EWAS statistics will 200 be deposited to the NCBI NIH Gene Expression Omnibus (this will be made 201 available upon acceptance by a peer-reviewed journal). 202
203

Results
204
Participant characteristics 205
The study sample included almost equal numbers of men and women, and equal 206 numbers of African American and Caucasian participants ( Table 1) . Baseline age 207 ranged from 70 to 78 years with an average age of 74 ± 2.4 years. Follow-up 208 DNA collection occurred at Year 6, with the exception of one participant with 209 follow up DNA collected at year 2 (Per7). Three participants had DNA from only 210 one time point, and thus these were included in the cross-sectional analysis but 211 not the time-dependent analysis. 212
During the Health ABC follow-up period, 7 participants (35%) were diagnosed 213 with cancer at times ranging from 6 months to 11 years from baseline ( Table 1) . 214
Cancer diagnoses included cancer of the prostate, colon, breast, and stomach, 215 as well as one case of leukemia. There were no differences in race, sex, or 216 baseline age or body mass index (BMI) between participants diagnosed with 217 cancer and those who remained cancer-free ( Table 2) . 
Quality of DNA methylation data and outlier identification 230
Unsupervised hierarchical clustering using the full set of probes showed that 15 231 of the individuals with longitudinal data paired within the same participant 232 (Additional file 1: Figure S1B ). The two exceptions, Per1 (cancer-free) and 233 Per9 (received cancer diagnosis at year 1 from baseline), did not cluster with 234 self, and this observation suggests potential intra-individual discordance in the 235 epigenetic data or increased cellular heterogeneity over time [24, 25] . To verify 236 that the non-pairing longitudinal samples are indeed from the same respective 237 participants, we performed the cluster analysis using only probes that were 238 flagged for overlap with SNPs, as these provide a signal for underlying genotype 239 variation. Using these SNP probes, all individuals with longitudinal samples, 240 including Per1 and Per9, paired appropriately with self (Additional file 2: 241
Figures S2).
Overall, the PC and cluster plots showed no batched effects and a 242 generally stable methylation pattern over time, with the exception of the two 243 participants. The QC analyses also identified Per13 as an outlier (Additional file 244 1: Figures S1B, S1C). Since Per13 was diagnosed with leukemia within 6 245 months of the first Health ABC visit, the distinct methylation pattern is consistent 246 with disease-related changes in leukocyte composition, and Per13 was excluded 247 from further analyses. 248
Longitudinal changes in CpG-based blood cell composition 249
We performed a CpG-based estimation of blood cell proportions [21] [22] [23] . We 250 evaluated differences in blood composition between baseline and Year 6. The 251 estimated proportion of CD8+ T-cells decreased, while the proportion of 252 granulocytes increased (Figure 1A, 1B ; Table 3 ). The proportions of the other 253 blood leukocyte subtypes remained relatively stable with no significant 254 differences between the two visits (estimates for all participants at both time 255 points are in Additional file 3: Table S1 ). We however note pronounced 256 changes in cell composition for Per1, one of the two participants that did not pair 257 with self in the hierarchical cluster; cellular heterogeneity partly explains the 258 discordance in the longitudinal data. 259 
266
Association between CpG-based blood cell estimates and cancer 267
We next examined if variation in blood cell composition was associated with 268 cancer diagnosis. We performed the analysis stratified by baseline and Year 6. 269
At baseline, none of the blood cells differentiated between those who developed 270 cancer and those who remained cancer-free. By Year 6, CD8+ T-cell proportion 271 was lower and granulocyte proportion was higher in the cancer-present group 272 with modest statistical significance (Figure 1A , B; Table 3) . 273
Global patterns in DNA methylation and association with cell composition 274
To examine the global patterns of variation in the methylome, we performed PCA 275 using the 739,648 probes. PC1 to PC5 captured 49% of the variance in the data 276 (Additional file 4: Data S1). Age and BMI were not correlated with the top 5 277
PCs. PC4 showed an association with race only at Year 6 (p-value = 0.02), and 278 PC5 with sex only at baseline (p-value = 0.02) (full results in Additional file 4: 279
Data S1). 280
Correlation with blood cell estimates showed that PC1, which accounts for 21% 281 of the variance, had a strong positive correlation with granulocytes and negative 282 correlations with lymphoid cells (T-cells, B-cells, and natural killer or NK cells) at 283 both baseline and Year 6 (full correlation matrix is provided in Additional file 4: 284 Data S1). PC5 was positively correlated with monocytes at both baseline and 285
Year 6 (Additional file 4: Data S1). 286
Global patterns in DNA methylation and association with cancer 287
We next evaluated whether the PCs could differentiate between individuals who 288 remained cancer-free compared to those who received a cancer diagnosis. PC1, 289 which captured the variation in cellular composition, showed a modest 290 association with cancer diagnosis at baseline and this became stronger by Year 291 6 (Table 3; Figure 1C ). The remaining 4 PCs were not associated with cancer 292 (Additional file 4: Data S1). 293
Differential CpG methylation between cancer and cancer-free groups 294
Following the PC analysis, we explored differential methylation at the level of 295 individual CpGs. Given the small sample size, we carried out simple t-tests to 296 compare the cancer-present vs. cancer-free groups at Year 6, the time when 297 PC1 showed a significant difference between the two groups. To control for 298 cellular heterogeneity and unmeasured confounding variables, we performed the 299 EWAS using residual (Figure 2) . 303
We considered the top 10 cancer-associated CpGs and evaluated these for 304 replication ( Table 4) . Among these top 10, 5 CpGs were associated with lower 305 methylation in the cancer group (cancer-hypomethylated), and the remaining 5 306 showed higher methylation in the cancer group (cancer-hypermethylated). To 307 test for replication, we cross-checked our results with those from Roos et al., 308 which evaluated for pan-cancer CpG biomarkers in blood using the previous 309 version of the Illumina Human Methylation 450K (HM450K) array. [16] . Of the top 310 10 CpGs in Table 4 , 5 probes were also represented in the HM450K array. The 311
CpG in the intron of RPTOR (cg08129331), which was cancer-hypomethylated in 312
Health ABC, also showed a similar hypomethylation in the Roos cohort at p-value 313 = 0.05. The CpG in the 3' UTR of MRPL44, which showed cancer-314 hypermethylation in Health ABC, showed hypermethylation in the Roos cohort at 315 p-value = 0.08. 316
Longitudinal changes in CpG methylation and diagnosis time 317
Since these CpGs differentiated between those who developed cancer and those 318 who remained cancer-free at Year 6, we then explored if the longitudinal changes 319 in methylation over time (deltaβ = Year 6 -baseline) could be related to time to 320 cancer diagnosis. For the 5 cancer-hypomethylated CpGs in Table 4 , we 321 predicted that the within-individual decline in methylation at Year 6 (negative 322 deltaβ) would be greater in those who were closer to diagnosis (positive 323 correlation with years to diagnosis or YTD). Inversely, for the 5 cancer-324 hypermethylated CpGs, we predicted that the within-individual increase in 325 methylation at Year 6 (positive deltaβ) would be greater in those closer to 326 diagnosis (negative correlation with YTD). With the exception of three probes that 327
showed Pearson correlation near 0, the remaining seven CpGs showed a 328 correlation pattern that was consistent with our predictions ( Figure 3 shows the longitudinal plots for these 3 331
CpGs and the correlation between deltaβ and YTD. 332 
Discussion
342
Summary 343
In this study, we evaluated two aspects of the aging methylome in an older group 344 of participants: (1) differences in DNA methylation patterns between those who 345 developed cancer and those who remained cancer-free, and (2) the longitudinal 346 trajectory over time. We used DNA purified from peripheral blood cells collected 347 epigenetic drift that occurs within a person, particularly at old age [24, 25] . We 356 found that cellular composition is a major source of variation and significantly 357 contributed to the variance explained by the primary principal component (PC1). 358
In terms of the biomarker utility of DNA methylation, our study highlighted a few 359
CpGs as potential biomarkers, and the dynamic changes over time at these 360 CpGs were correlated with time to cancer diagnosis. 361
Cellular heterogeneity as both informative and a potential confounder 362
Cellular composition is clearly a major correlate of DNA methylation and can be a 363 confounding variable when we attempt to relate the methylome derived from 364 heterogeneous tissue to aging and disease [29] . The composition of cells in 365 circulating blood can be influenced by natural immune aging and also by 366 numerous correlated health variables including lifestyle, infectious disease, 367 leukemia or similar cancers, and environmental exposures. For example, one of 368 the most consistent features of the aging immune system involves thymic 369 involution and the time-dependent decline in both the absolute number and the 370 relative percent of naïve CD8+ T-cells [30] [31] [32] [33] . A strategy to estimate the 371 composition of cells from DNA methylation data is to rely on specific CpGs that 372 are known to be strong cell-specific markers and can serve as surrogate 373 measures of cellular sub-types [21] [22] [23] . With the current data, we applied this in 374 silico approach to estimate the relative proportions of CD8+ T-cells, CD4+ T-375 cells, B-cells, NK cells, granulocytes, and monocytes. The DNA methylation-376 based estimates of cell proportions showed a decrease in CD8+ T-cells and an 377 increase in granulocytes over the course of 5 years. By Year 6 from baseline, the 378 proportion of CD8+ T-cells was lower and proportion of granulocytes higher in the 379 cancer-present group relative to the cancer-free group. Since the first few PCs 380 captured the variance due to cellular composition, PC1 also showed a similar 381 change over time. PC1 showed a slight distinction between the cancer-present 382 vs. cancer-free groups even at baseline, and this became more pronounced by 383 Year 6. These differences are likely because PC1 summarized the changes in 384 the composition of multiple cell subtypes including those that were not estimated 385 using the reference set of cell-specific CpGs. PCA may therefore be more 386 effective at capturing the composite changes arising from different cellular 387 subtypes and may also be more disease-informative than the estimated 388 proportion of major cell types. 389
Our observations are consistent with the general decrease in lymphoid cells and 390 increase in myeloid cells during aging [30] [31] [32] . In line with the lower lymphocytes 391 and higher granulocytes in the cancer group, work from both model organisms 392 and humans have shown an inverse relationship between lymphocytes and 393 granulocytes with lower B-cells and T-cells, and higher neutrophils being 394 associated with higher mortality risk [34] [35] [36] . While we cannot disentangle the 395 inter-correlations between aging, cell composition, and methylation patterns, our 396 results do demonstrate that DNA methylation data derived from peripheral blood 397 in older participants can be used to glean information on their cellular profiles, 398 and this in turn can be related to their health and disease status. 399
Identifying (pan)cancer CpGs 400
Following the cell estimation and PC analysis, we took an EWAS approach to 401 examine differential methylation at the level of individual CpGs. Previous studies 402 have already demonstrated that DNA methylation patterns can provide a 403 powerful "pan-cancer" biomarker-i.e., an epigenetic signature of cancer that can 404 serve as a general biomarker for the presence of cancer, and possibly different 405 cancer types as well [37, 38] . The majority of these studies have involved 406 comparisons between normal vs. tumor tissue, or are dependent on the shedding 407 of cell-free DNA from the primary site of cancer and therefore are indicators of in 408 situ changes that occur in tumor cells [37, [39] [40] [41] [42] [43] . Relatively few studies have 409 taken a prospective approach that involves sample collection prior to disease 410 diagnosis [44, 45] , and even fewer have attempted to track longitudinal changes 411 across multiple timepoints [14, 15] . Nevertheless, these few prospective studies 412 have shown that both the global patterns and DNA methylation at specific CpG 413 sites can be indicators of cancer, and even more strikingly, that some of these 414 generalized changes can be detected in circulating blood cells [14, 15, 44, 45] . 415
Given this background, our goal was to examine if we can also detect similar 416 "pan-cancer" CpG biomarkers. We used a simple approach and contrasted DNA 417 methylation between the cancer-present and cancer-free groups at Year 6, the 418 time when we expect the differences to be more pronounced. Despite the small 419 To gather additional lines of evidence, we examined if the association with 436 cancer for these CpGs can be replicated in an independent dataset, and if the 437 cognate genes have been previously related to cancer or tumorigenesis. For 438 replication we referred to the work by Roos et al. [16] . While the study by Roos et 439 al. compared cancer-discordant monozygotic twins and involved a much wider 440 age range, some design features common to our study are: (1) the cancer group 441 included samples collected from individuals who had already received cancer 442 diagnosis (post-diagnosis) and from individuals within 5 years to diagnosis (pre-443 diagnosis), (2) a variety of cancer types were represented, and (3) genome-wide 444 DNA methylation was measured using peripheral blood cells. In the Health ABC 445 Study set, 3 participants (excluding Per13 with leukemia) had been diagnosed by 446
Year 6, and the remaining participants received a diagnosis 1-5 years after Year 447 6. Since the Roos dataset was generated on the previous version of the Illumina 448 DNA methylation arrays (HM450K), only 5 of the top 10 probes were represented 449 on that array and could be evaluated for replication. Only the CpG in the intron of 450 RPTOR (cg08129331) was replicated and was also associated with a 451 consistently lower methylation in the cancer group (p-value = 0.05 in Roos 452 study REC8 has a more consistent tumor suppressive role and promoter 479 hypermethylation and suppression of its expression occurs in tumor cells [57] [58] [59] [60] . 480
In the Health ABC samples, the CpG in the promoter (cg07516252) was 481 hypomethylated and not hypermethylated in the group that received cancer 482 diagnosis. The rate of promoter hypomethylation was also significantly correlated 483 with time to diagnosis (R = 0.89). Since our study is blood-based and does not 484 stem from the primary tumor site, the hypomethylation may indicate aberrant 485 methylation over time in individuals, with greater changes observed in those 486 individuals who are closer to clinical manifestations. However, this promoter CpG 487 did not replicate in the Roos data. 488 KCNQ1 is another tumor suppressor gene, and loss of its expression is 489 considered to be an indicator of metastasis and poor prognosis [61] [62] [63] . There is 490 also evidence that the reduction in KCNQ1 expression in cancer cells may be 491 mediated by promoter hypermethylation [62, 64] . In the Health ABC samples, the 492 intronic CpG (cg05808305) had much lower methylation in the cancer group and 493 was significant only at Year 6. Among the known and potential tumor suppressive 494 genes, only the intronic CpG in ZSWIM5 (cg04429789) was associated with 495 hypermethylation in the Health ABC cancer diagnosed group; for this CpG, the 496 positive deltaβ was significantly correlated with time to diagnosis with greater 497 positive change in those closer to receiving a diagnosis (R = -0.81). So far, we 498 have found only one study showing that the expression of ZSWIM5 inhibits 499 malignant progression [65] . We could not test replication for the CpG in ZSWIM5 500 since this was not a probe that was included in the HM450K array. 501
Based on the multiple lines of evidence, we highlight the CpG in the first intron of 502 RPTOR (cg08129331) as a stronger potential pan-cancer biomarker as this 503 specific CpG was replicated in the Roos data. This gene codes for a member of 504 the mTOR protein complex, which plays a key role in cell growth and 505 proliferation, and dysregulation of this signaling pathway is a common feature in 506 cancers [66] . The lower methylation of this CpG in cancer-free individuals in 507
Health ABC was significant only in Year 6. For the longitudinal change, the 508 correlation between the deltaβ and time to diagnosis was significant for 509 cg08129331. This specific CpG has been previously presented as a marker to 510 differentiate between different medulloblastoma subtypes [67] . Another study has 511 also indicated that the decrease in methylation in RPTOR measured in peripheral 512 blood may be a biomarker for breast cancer, although this failed replication in a 513 follow-up study [68, 69] . Similar to REC8, there was more negative change in β -514 value from Year 1 to 6 in individuals closer to receiving a cancer diagnosis. 515
Limitations 516
The present work was carried out in a very small and heterogenous group of 517 participants. The cancer-present group consisted of different types of cancers, 518
and there was a combination of individuals who received the diagnosis before 519 and after Year 6. The differences in DNA methylation should therefore be 520 interpreted as potential correlates rather than predictive indicators of disease. 521
Due to the limitation in sample number, we performed simple t-test comparisons 522 rather than more complex regressions such as mixed modeling. Furthermore, we 523 considered the cancer diagnosis as the main outcome variable and did not 524 account for cancer type, stage or progression. Additionally, while we took steps 525 to statistically correct for immune cell composition, the data was derived from 526 white blood cells from older participants. The in-silico approach to estimate cell 527 composition cannot discern the finer repertoire of cellular subtypes that are 528 known to change particularly in older individuals. The results we present 529 therefore require further replication in a larger cohort. Our study is mainly a 530 demonstration of concept that highlights the utility of longitudinal blood collection 531 and the potential information on health and disease that can be gained by 532 tracking dynamic changes in the methylome. 533 534 535
Conclusion 536
Taken together, our analysis detected global changes in the methylome that are 537 partly due to cellular heterogeneity and also due to changes at specific CpGs that 538 could indicate cancer development and progression. From the multiple lines of 539 evidence, we posit methylation in RPTOR as a potential biomarker of cancer that 540 justifies further investigation and validation. 541 writing of the manuscript; EMS: helped with interpretation and contributed to the 572 final manuscript; KM designed the study, contributed to data analysis and 573 interpretation, and prepared the manuscript. 574
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